Advertisement

The Role of Cytokines in Cancer Cachexia

  • Josep M. Argilés
  • Sílvia Busquets
  • Rodrigo Moore-Carrasco
  • Francisco J. López-Soriano

Abstract

The cachectic syndrome, characterised by marked weight loss, anorexia, asthaenia, and anaemia, is invariably associated with the presence and growth of the tumour and leads to a malnutrition status due to the induction of anorexia or decreased food intake. In addition, the competition for nutrients between the tumour and the host leads to an accelerated starvation state that promotes severe metabolic disturbances in the host, including hypermetabolism, which leads to decreased energetic efficiency. Although the search for the cachectic factor(s) started a long time ago, and although many scientific and economic efforts have been devoted to its discovery, we are still far from a complete understanding of cancer cachexia. The chapter discusses the different signalling pathways, particularly the role of transcriptional factors, involved in muscle wasting. The main aim is to summarise and evaluate the different molecular mechanisms and catabolic mediators (both humoral and tumoural) involved in cancer cachexia, since they may represent targets for promising future clinical investigations.

Keywords

Brown Adipose Tissue Leukaemia Inhibitory Factor Cancer Cachexia C2C12 Myoblast UCP3 mRNAs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    López-Soriano J, Carbó N, Tessitore L et al (1999) Leptin and tumour growth in the rat. Int J Cancer 81:726–729PubMedCrossRefGoogle Scholar
  2. 2.
    Sato T, Meguid MM, Miyata G et al (2002) Does leptin really influence cancer anorexia? Nutrition 18:82–83PubMedCrossRefGoogle Scholar
  3. 3.
    Kowalczuk A, Wiecek A, Franek E, Kokot F (2001) Plasma concentration of leptin, neuropeptide Y and tumour necrosis factor alpha in patients with cancers, before and after radioand chemotherapy. Pol Arch Med Wewn 106:657–668PubMedGoogle Scholar
  4. 4.
    Tessitore L, Vizio B, Jenkins O et al (2000) Leptin expression in colorectal and breast cancer patients. Int J Mol Med 5:421–426PubMedGoogle Scholar
  5. 5.
    Brown DR, Berkowitz DE, Breslow MJ (2001) Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. J Clin Endocrinol Metab 86:162–166PubMedCrossRefGoogle Scholar
  6. 6.
    Aleman MR, Santolaria F, Batista N et al (2002) Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 19:21–26PubMedCrossRefGoogle Scholar
  7. 7.
    Mantovani G, Macciò A, Mura L et al (2000) Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 78:554–561PubMedCrossRefGoogle Scholar
  8. 8.
    Mantovani G, Macciò A, Madeddu C et al (2001) Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med 79:406–414PubMedCrossRefGoogle Scholar
  9. 9.
    Plata-Salaman CR (2000) Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 16:1009–1012PubMedCrossRefGoogle Scholar
  10. 10.
    Chance WT, Balasubramaniam A, Dayal R et al (1994) Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumour-bearing rats. Life Sci 54:1869–1874PubMedCrossRefGoogle Scholar
  11. 11.
    King PJ, Widdowson PS, Doods H, Williams G (2000) Effect of cytokines on hypothalamic neuropeptide Y release in vitro. Peptides 21:143–146PubMedCrossRefGoogle Scholar
  12. 12.
    Laviano A, Russo M, Freda F, Rossi-Fanelli F (2002) Neurochemical mechanisms for cancer anorexia. Nutrition 18:100–105PubMedCrossRefGoogle Scholar
  13. 13.
    Bing C, Taylor S, Tisdale MJ, Williams G (2001) Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem 79:1004–1012PubMedCrossRefGoogle Scholar
  14. 14.
    Strassmann G, Fong M, Freter CE et al (1993) Suramin interfers with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest 92:2152–2159PubMedGoogle Scholar
  15. 15.
    Barton BE, Cullison J, Jackson J, Murphy T (2000) A model that reproduces syndromes associated with human multiple myeloma in nonirradiated SCID mice. Proc Soc Exp Biol Med 223:190–197PubMedCrossRefGoogle Scholar
  16. 16.
    Barton BE, Murphy TF (2001) Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine 16:251–257PubMedCrossRefGoogle Scholar
  17. 17.
    Negri DR, Mezzanzanica D, Sacco S et al (2001) Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. Cytokine 15:27–38PubMedCrossRefGoogle Scholar
  18. 18.
    Matthys P, Heremans H, Opdenakker G, Billiau A (1991) Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur J Cancer 27:182–187PubMedCrossRefGoogle Scholar
  19. 19.
    Henderson JT, Mullen BJ, Roder JC (1996) Physiological effects of CNTF-induced wasting. Cytokine 8:784–793PubMedCrossRefGoogle Scholar
  20. 20.
    Wang MC, Forsberg NE (2000) Effects of ciliary neurotrophic factor (CNTF) on protein turnover in cultured muscle cells. Cytokine 12:41–48PubMedCrossRefGoogle Scholar
  21. 21.
    Busquets S, Sanchés D, Alvarez B et al (1998) In the rat, TNF-a administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis? FEBS Lett 440:348–350PubMedCrossRefGoogle Scholar
  22. 22.
    Busquets S, Aranda X, Ribas-Carbó M et al (2003) Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. Cytokine 22:1–4PubMedCrossRefGoogle Scholar
  23. 23.
    Argilés JM, López-Soriano FJ (1998) Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care 1:245–251PubMedCrossRefGoogle Scholar
  24. 24.
    Bossola M, Muscaritoli M, Costelli P et al (2001) Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol 280:R1518–R1523Google Scholar
  25. 25.
    Baracos VE (2000) Regulation of skeletal-muscleprotein turnover in cancer-associated cachexia. Nutrition 16:1015–1018PubMedCrossRefGoogle Scholar
  26. 26.
    Alvarez B, Quinn LS, Busquets S et al (2002) Tumour necrosis factor-alpha exerts interleukin-6-dependent and-independent effects on cultured skeletal muscle cells. Biochem Biophys Acta 1542:66–72PubMedCrossRefGoogle Scholar
  27. 27.
    Sharma R, Anker SD (2002) Cytokines, apoptosis and cachexia: the potential for TNF-α antagonism. Int J Cardiol 85:161–171PubMedCrossRefGoogle Scholar
  28. 28.
    Van Royen M, Carbó N, Busquets S et al (2000) DNA fragmentation occurs in skeletal muscle during tumour growth: a link with cancer cachexia? Biochem Biophys Res Commun 270:533–537PubMedCrossRefGoogle Scholar
  29. 29.
    Belizario JE, Lorite MJ, Tisdale MJ (2001) Cleavage of caspases-1,-3,-6,-8 and-9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer 84:1135–1140PubMedCrossRefGoogle Scholar
  30. 30.
    Carbó N, Busquets S, van Royen M et al (2002) TNFa is involved in activating DNA fragmentation in murine skeletal muscle. Br J Cancer 86:1012–1016PubMedCrossRefGoogle Scholar
  31. 31.
    Dunlop RJ, Campbell CW (2000) Cytokines and advanced cancer. J Pain Symptom Manage 20:214–232PubMedCrossRefGoogle Scholar
  32. 32.
    Cahlin C, Korner A, Axelsson H et al (2000) Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferongamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 60:5488–5493PubMedGoogle Scholar
  33. 33.
    Costa G, Holland JF (1966) Effects of Krebs-2 carcinoma on the lipid metabolism of male Swiss mice. Cancer Res 22:1081–1083Google Scholar
  34. 34.
    Kitada S, Hays EF, Mead JF (1981) Characterization of a lipid mobilizing factor from tumors. Prog Lipid Res 20:823–826PubMedCrossRefGoogle Scholar
  35. 35.
    Masuno H, Yamasaki N, Okuda H (1981) Purification and characterization of a lipolytic factor (toxohormone L) from cell free fluid of ascites sarcoma 180. Cancer Res 41:284–288PubMedGoogle Scholar
  36. 36.
    Khan S, Tisdale MJ (1999) Catabolism of adipose tissue by a tumour-produced lipid metabolising factor. Int J Cancer 80:444–447PubMedCrossRefGoogle Scholar
  37. 37.
    Hirai K, Hussey HJ, Barber 0MD et al (1998) Biological evaluation of a lipid-mobilising factor isolated from the urine of cancer patients. Cancer Res 58:2359–2365PubMedGoogle Scholar
  38. 38.
    Hirai K, Ishiko O, Tisdale M (1997) Mechanism of depletion of liver glycogen in cancer cachexia. Biochem Biophys Res Commun 241:49–52PubMedCrossRefGoogle Scholar
  39. 39.
    Ishiko O, Yasui T, Hirai K et al (1999) Lipolytic activity of anemia-inducing susbtance from tumor-bearing rabbits. Nutr Cancer 33:201–205PubMedCrossRefGoogle Scholar
  40. 40.
    Todorov P, Cariuk P, McDevitt T et al (1996) Characterization of a cancer cachectic factor. Nature 22:739–742CrossRefGoogle Scholar
  41. 41.
    Lorite MJ, Cariuk P, Tisdale MJ (1997) Induction of muscle protein degradation by a tumour factor. Br J Cancer 76:1035–1040PubMedGoogle Scholar
  42. 42.
    Wigmore SJ, Todorov PT, Ross JA et al (2000) Characteristics of patients with pancreatic cancer expressing a novel cancer cachexia factor. Br J Surgery 87:53–58CrossRefGoogle Scholar
  43. 43.
    Lorite MJ, Thompson MG, Drake JL et al (1998) Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 78:850–856PubMedGoogle Scholar
  44. 44.
    Smith HJ, Lorite MJ, Tisdale MJ (1999) Effects of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid. Cancer Res 59:5507–5513PubMedGoogle Scholar
  45. 45.
    Penner CG, Gang G, Wray C et al (2001) The transcription factors NF-kappaB and AP-1 are differentially regulated in skeletal muscle during sepsis. Biochem Biophys Res Commun 281:1331–1336PubMedCrossRefGoogle Scholar
  46. 46.
    Busquets S, Carbó N, Almendro V et al (2001) Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Lett 167:33–38PubMedCrossRefGoogle Scholar
  47. 47.
    Fernandez-Celemin L, Pasko N, Blomart V, Thissen JP (2002) Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. Am J Physiol 283:E1279–E1290Google Scholar
  48. 48.
    Li YP, Schwartz RJ, Waddell ID et al (1998) Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J 12:871–880PubMedGoogle Scholar
  49. 49.
    Brenner DA, O’Hara M, Angel P et al (1989) Prolonged activation of jun and collagenase genes by tumor necrosis factor-alpha. Nature 337:661–663PubMedCrossRefGoogle Scholar
  50. 50.
    Thinakaran G, Ojala J, Bag J (1993) Expression of cjun/AP-1 during myogenic differentiation in mouse C2C12 myoblasts. FEBS Lett 319:271–276PubMedCrossRefGoogle Scholar
  51. 51.
    Penner G, Gang G, Sun X et al (2002) C/EBP DNAbinding activity is upregulated by a glucocorticoiddependent mechanism in septic muscle. Am J Physiol 282:R439–R444Google Scholar
  52. 52.
    Guttridge DC, Mayo MW, Madrid LV et al (2000) NFkappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289:2363–2366PubMedCrossRefGoogle Scholar
  53. 53.
    Coletti D, Yang E, Marazzi G, Sassoon D (2002) TNFα inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J 21:631–642PubMedCrossRefGoogle Scholar
  54. 54.
    Puigserver P, Rhee J, Lin J et al (2001) Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell 8:971–982PubMedCrossRefGoogle Scholar
  55. 55.
    Balazs C, Kiss E (1994) Immunological aspects of the effect of pentoxifylline. Acta Microbiol Immunol Hung 41:121–126PubMedGoogle Scholar
  56. 56.
    Goldberg RM, Loprinzi CL, Mailliard JA et al (1995) Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 13:2856–2859PubMedGoogle Scholar
  57. 57.
    Peuckmann V, Fisch M, Bruera E (2000) Potential novel uses of thalidomide: focus on palliative care. Drugs 60:273–292PubMedCrossRefGoogle Scholar
  58. 58.
    Costelli P, Carbó N, Tessitore L et al (1993) Tumor necrosis factor-α mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 92:2783–2789PubMedCrossRefGoogle Scholar
  59. 59.
    Reinhart K, Wiegand-Lohnert C, Grimminger F et al (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebocontrolled, dose-ranging study. Crit Care Med 24:733–742PubMedCrossRefGoogle Scholar
  60. 60.
    Mori K, Fujimoto-Ouchi K, Ishikawa T et al (1996) Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int J Cancer 67:849–855PubMedCrossRefGoogle Scholar
  61. 61.
    Quinn LS, Haugk KL, Grabstein KH (1995) Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology 136:3669–3672PubMedCrossRefGoogle Scholar
  62. 62.
    Carbó N, López-Soriano J, Costelli P et al (2000) Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer 83:526–531PubMedCrossRefGoogle Scholar
  63. 63.
    Okamoto T (2002) NSAID zaltoprofen improves the decrease in body weight in rodent sickness behavior models: proposed new applications of NSAID. Int J Mol Med 9:369–372PubMedGoogle Scholar
  64. 64.
    Niu Q, Li T, Liu A (2001) Cytokines in experimental cancer cachexia. Zhonghua Zhong Liu Za Zhi 23:382–384PubMedGoogle Scholar
  65. 65.
    Kawamura I, Morishita R, Tomita N et al (1999) Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther 6:91–97PubMedCrossRefGoogle Scholar
  66. 66.
    Kawamura I, Morishita R, Tsujimoto S et al (2001) Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther 8:905–912PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Josep M. Argilés
    • 1
  • Sílvia Busquets
    • 1
  • Rodrigo Moore-Carrasco
    • 1
  • Francisco J. López-Soriano
    • 1
  1. 1.Cancer Research Group, Department of Biochemistry and Molecular BiologyUniversity of BarcelonaBarcelonaSpain

Personalised recommendations